Jessica Wapner

All articles by Jessica Wapner

Novel immunotherapies and small molecule pathway inhibitors are transforming the standard of care for some of the most challenging lymphoma subtypes.

Targeted Therapy for Non-Hodgkin Lymphoma: Current Progress and Future Plans

Jessica Wapner

September 8, 2020

Novel immunotherapies and small molecule pathway inhibitors are transforming the standard of care for some of the most challenging lymphoma subtypes.

$In the phase 2 ZUMA-2 study, KTE-X19 CAR-T therapy showed a lasting clinical benefit and manageable side effects in relapsed/refractory mantle cell lymphoma.$

Lymphoma

High Response Rates to CAR-T Seen in Mantle Cell Lymphoma

Jessica Wapner

April 8, 2020

In the phase 2 ZUMA-2 study, KTE-X19 CAR-T therapy showed a lasting clinical benefit and manageable side effects in relapsed/refractory mantle cell lymphoma.

Next post in Lymphoma

Jessica Wapner

All articles by Jessica Wapner

Targeted Therapy for Non-Hodgkin Lymphoma: Current Progress and Future Plans

High Response Rates to CAR-T Seen in Mantle Cell Lymphoma

Requirements for Better Outcomes for Patients With Non-Hodgkin Lymphoma in Sub-Saharan Africa